MedTrace Logo

Efficacy of Intravenous Immunoglobulin in Management of Rh and ABO Incompatibility Disease

NCT03130517 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-06-27

No results posted yet for this study

Summary

hemolytic disease of newborn is an important cause of hyperbilirubinemia with significant morbidity and mortality in neonatal period. intravenous immunoglobulin has widely used in management of hemolytic disease of new born

Conditions

  • Haemolysis Neonatal

Interventions

DRUG

intravenous immunoglobulin

giving intravenous immunoglobulin to neonates included in inclusion criteria in a dose of 0.5-1 gm

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
48 Hours
Max Age
30 Days
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-01
Primary Completion
2018-12-31
Completion
2018-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03130517 on ClinicalTrials.gov